Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

The Royal Institution for the Advancement of Learning/McGill University

$100,000.00

Microbead-in-droplet assay for characterizing Chimeric Antigen Receptor T-cells activation by tumor cells in co-culture droplets

FY 2021-22 · 2021-10-01

Summary
The project aims to characterize the functionality of engineered immune cells (e.g. CAR T-cells) by activating them with tumor-specific antigens (e.g. CD-19) and through their interaction with isolated circulating tumor cells (CTCs). To achieve this goal, the CAR T-cells and the isolated cells will be brought together and encapsulated in droplets to promote cellular interactions. The cells will then be incubated for CAR T-cell activation, and the activated CAR T-cells will be interrogated by analyzing the cytokines output using a microbead-in-droplet multiplex sandwich immunoassay developed in this project. The novel technology proposed herein is currently unavailable on the market and has the potential to significantly affect the way that cell therapy products are assessed and how quality control is performed.
Program
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Location
Montreal|Montréal, Quebec, Canada
Recipient Type
Academia
Business Number
119128981
Type
Grant
Source
Proactive Disclosure - Grants and Contributions

As published

Reference Number
172-2021-2022-Q2-979803
Amendment Number
0
Agreement Type
Grant
Recipient Type
S
Recipient Business Number
119128981
Recipient Legal Name
The Royal Institution for the Advancement of Learning/McGill University
Recipient Country
CA
Recipient Province or Territory
QC
Recipient City
Montreal|Montréal
Recipient Postal Code
H3A 0G4
Federal Riding
Ville-Marie–Le Sud-Ouest–Île-des-Sœurs
Federal Riding (French)
Ville-Marie–Le Sud-Ouest–Île-des-Soeurs
Federal Riding Number
24077
Program Name
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Name (French)
Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D
Program Purpose
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
Program Purpose (French)
Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires.
Agreement Title
Microbead-in-droplet assay for characterizing Chimeric Antigen Receptor T-cells activation by tumor cells in co-culture droplets
Agreement Title (French)
Essai de microbilles en gouttelettes pour caractériser l’activation des cellules T des récepteurs d’antigènes chimériques par les cellules tumorales dans des gouttelettes de coculture.
Agreement Number
979803
Agreement Value
$100,000.00
Agreement Start Date
2021-10-01
Agreement End Date
2022-09-30
Description
The project aims to characterize the functionality of engineered immune cells (e.g. CAR T-cells) by activating them with tumor-specific antigens (e.g. CD-19) and through their interaction with isolated circulating tumor cells (CTCs). To achieve this goal, the CAR T-cells and the isolated cells will be brought together and encapsulated in droplets to promote cellular interactions. The cells will then be incubated for CAR T-cell activation, and the activated CAR T-cells will be interrogated by analyzing the cytokines output using a microbead-in-droplet multiplex sandwich immunoassay developed in this project. The novel technology proposed herein is currently unavailable on the market and has the potential to significantly affect the way that cell therapy products are assessed and how quality control is performed.
Description (French)
Le projet vise à caractériser la fonctionnalité des cellules immunitaires modifiées (p. ex., les cellules CAR-T) en les activant avec des antigènes spécifiques de la tumeur (p. ex., CD-19) et par leur interaction avec des cellules tumorales circulantes isolées. Pour atteindre cet objectif, les cellules CAR-T et les cellules isolées seront réunies et encapsulées dans des gouttelettes pour favoriser les interactions cellulaires. Les cellules seront ensuite incubées pour l’activation des cellules CAR-T, et ces dernières seront examinées en analysant la production de cytokines à l’aide d’un dosage sandwich multiplex à microbilles dans des gouttelettes, lequel est développé dans le cadre de ce projet. La nouvelle technologie proposée ici n’est actuellement pas disponible sur le marché et a le potentiel d’affecter de manière appréciable la manière dont les produits de thérapie cellulaire sont évalués et dont le contrôle de qualité est effectué.
NAICS Code
541710
Expected Results
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Expected Results (French)
À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides.
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada